Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The DASISION chronic myeloid leukaemia trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.02.11
Views: 7407

Dr Neil Shah - University of California, San Francisco, USA

Dr Neil Shah speaks to ecancer.tv about the DASISION trial (Dasatinib versus Imatinib Study in Treatment-Naïve CML Patients). This trial was established to evaluate the efficacy of dasatinib in the treatment of CML patients who are unresponsive or unsuitable for imatinib, but has since progressed to compare dasatinib directly with imatinib to identify which is the more effective first line therapy. The DASISION trial found that after twelve months dasatinib achieved a higher level of response than imatinib. Dr Shah discusses these results and their clinical implications and talks about the possibility of CML becoming a truly chronic disease that can be controlled without developing resistance, using a combination of first, second and third generation TKIs.

This programme is supported by an educational grant from Bristol-Myers Squibb.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation